Immune Netw.  2012 Apr;12(2):66-69. 10.4110/in.2012.12.2.66.

Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines

Affiliations
  • 1Office of Biomedical Professors, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea. andyjosh@skku.edu
  • 2College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea.
  • 3Department of Microbiology & Immunology, Inje University College of Medicine, Busan 614-735, Korea.

Abstract

The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-gamma and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.

Keyword

Indoledione derivative; Calreticulin; Immunological death; Human tumor cells

MeSH Terms

Calreticulin
Cell Death
Cell Line
Cell Line, Tumor
Colon
Humans
Interleukin-12
Stomach Neoplasms
Calreticulin
Interleukin-12
Full Text Links
  • IN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr